Clinical trials: Disorder of Circulatory System
Hemorrhoids
A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids
The purpose of this study is to compare the therapeutic effect and safety of compound carraghenates cream with Mayinglong musk hemorrhoid (swollen veins in the lower part of the rectum or anus) ointment in the treatment of…
- Trial name
- NCT01881282
- Testing
- Carraghenates Cream, Mayinglong Musk Hemorrhoid Ointment
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Liver Cirrhosis
Alfapump-albumin Replacement Therapy
The study will be a single centre, open-label trial. The patients will have a diagnosis of refractory ascites and will meet specified inclusion/exclusion criteria Informed consent will be obtained from all patients.
- Trial name
- NCT02448160
- Testing
- alfapump, salt-poor Human Albumin solution
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Sequana Medical N.V.
Multiple Myeloma, Multiple Myeloma in Relapse
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission
- Trial name
- NCT03650491
- Testing
- FOR46
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fortis Therapeutics, Inc.
Peripheral Arterial Disease
Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
To evaluate the safety and effectiveness of the Cardio Flow FreedomFlow™ Orbital Circumferential Atherectomy System for atherosclerotic plaque removal and vessel compliance modification in de novo native target lesions in the…
- Trial name
- FASTII (NCT03635190)
- Testing
- Orbital Circumferential Atherectomy
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Cardio Flow, Inc.
Multiple Myeloma, Relapsed Cancer
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease
- Trial name
- NCT05641324
- Testing
- ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 4 people
- Sponsor
- Anaveon AG
Paroxysmal Atrial Fibrillation
PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation
PEFCAT II: Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation
- Trial name
- PEFCATII (NCT04170608)
- Testing
- FARAPULSE Endocardial Multi Ablation System
- Where
- 2 sites in Croatia, Czechia
- Volunteers
- 10 people
- Sponsor
- Boston Scientific Corporation
Chronic Ulcers, Diabetic Foot Ulcers (DFU)
Case Series of StimLabs Dehydrated Human Umbilical Cord Particulate for Acute and Chronic Wounds
The purpose of this observational case series is to assess the use of Corplex P as a resorbable particulate device used to cover, protect, and provide a moist wound environment when added to the standard of care treatment of…
- Conditions
- Chronic Ulcers, Diabetic Foot Ulcers (DFU), DFU, Ulcer
- Trial name
- NCT07414368
- Testing
- Corplex P is used to cover, protect, and provide a moist wound environment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- StimLabs
Multiple Myeloma
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
- Trial name
- NCT01695590
- Testing
- PRLX 93936
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Prolexys Pharmaceuticals
Carotid Artery Diseases
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
The study objective is to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy
- Trial name
- NCT05365490
- Testing
- Transcarotid Artery Revascularization (TCAR)
- Where
- 53 sites in United States
- Volunteers
- 344 people
- Sponsor
- Silk Road Medical
ANCA Associated Vasculitis (AAV)
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
- Trial name
- NCT06868290
- Testing
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Where
- 39 sites in United States, Brazil and 6 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, NonHodgkin Lymphoma
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
- Trial name
- NCT02978235
- Testing
- TAS4464
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Taiho Oncology, Inc.
Primary Prevention of Sudden Cardiac Arrest, Secondary Prevention of Sudden Cardiac Arrest
S-ICD® System Post Approval Study
The purpose of the S-ICD Post Approval Study is to document long term safety and effectiveness outcomes associated with the implantation of the SQ-RX pulse generator and Q-TRAK electrode in a commercial clinical setting.
- Trial name
- NCT01736618
- Testing
- S-ICD System
- Where
- 87 sites in United States
- Volunteers
- 1,766 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Coronary Restenosis
Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.
To determine in a randomized controlled trial (RCT) whether percutaneous coronary intervention - in patients with in-stent restenosis in either bare metal stents or drug eluting stents - with the Pantera Lux balloon is…
- Trial name
- BIOLUX-RCT (NCT01651390)
- Testing
- Percutaneous coronary intervention
- Where
- 14 sites in Germany, Latvia
- Volunteers
- 231 people
- Sponsor
- Biotronik AG
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
Hypertension
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.
- Trial name
- NCT00367978
- Testing
- Amlodipine/benazepril
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis
Aortic Dissection Type B, Intramural Hematoma
CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions
The goal of this prospective, interventional, multicentre, single-arm performance objective study is to evaluate efficacy and safety of Cratos™ Branch Stent Graft System in treatment of lesions (dissection, IMH and PAU in…
- Conditions
- Aortic Dissection Type B, Intramural Hematoma, Penetrating Aortic Ulcer
- Trial name
- NCT05874206
- Testing
- Cratos™ Stent Graft
- Where
- Switzerland
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd
Refractory or Relapsed Multiple Myeloma
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple…
- Trial name
- NCT06952478
- Testing
- CT-P44(Daratumumab), Darzalex Faspro(Daratumumab)
- Where
- Taiwan
- Volunteers
- 473 people
- Sponsor
- Celltrion
Intracranial Aneurysms
TRAIL: Treatment of Intracranial Aneurysms With LVIS® System
A prospective, multicenter, observational assessment of the safety and effectiveness of the LVIS® device in the treatment of wide necked intracranial aneurysms.
- Trial name
- TRAIL (NCT02921711)
- Testing
- LVIS®
- Volunteers
- 90 people
- Sponsor
- Microvention-Terumo, Inc.
Cerebral Arteriovenous Malformation
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)
The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date.
- Trial name
- CHOICE (NCT03413852)
- Testing
- SQUID non-adhesive liquid embolic agent
- Where
- 19 sites in Belgium, Denmark and 3 more
- Volunteers
- 111 people
- Sponsor
- Embo-Flüssigkeiten A.G.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.